Fecal Microbiota Transplantation Could Be First-Line Therapy for C. Difficile
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 25, 2025 -- Fecal microbiota transplantation (FMT) could be considered as first-line therapy for primary Clostridioides difficile infection (CDI), according to a study published online June 17 in the Annals of Internal Medicine.
Frederik Emil Juul, M.D., Ph.D., from Oslo University Hospital in Norway, and colleagues examined the efficacy and safety of FMT in primary CDI in a randomized, open-label, noninferiority trial. Adults with CDI and no previous CDI within 365 days before enrollment were randomly assigned to receive FMT without antibiotic pretreatment or oral vancomycin, 125 mg four times daily for 10 days.
The researchers found that clinical cure and no disease recurrence within 60 days without additional treatment was observed in 66.7 percent of 51 patients receiving FMT versus 61.2 percent of 49 patients receiving vancomycin (difference, 5.4 percentage points; 95.2 percent confidence interval, −13.5 to 24.4 percentage points; P for noninferiority <0.001). Additional C. difficile treatment was received by 11 and four patients in the FMT and vancomycin groups, respectively. Clinical cure at day 14 and no recurrence with or without additional treatment was observed in 78.4 and 61.2 percent of patients receiving FMT and vancomycin, respectively. The groups did not have any significant differences in adverse events.
"FMT even showed a 5.4 percent numerical superiority to vancomycin, which, although not statistically significant, indicates that FMT has the potential to change the current practice of antibiotic therapy and may establish FMT as a first-line treatment for primary CDI," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Oral Ondansetron Beneficial for Pediatric Gastroenteritis-Linked Vomiting
FRIDAY, July 18, 2025 -- For children with gastroenteritis-associated vomiting, the provision of oral ondansetron after an emergency department visit is associated with a lower...
Bariatric Surgery Complications Increase With Initial Body Mass Index
TUESDAY, July 1, 2025 -- The higher a person’s body mass index (BMI), the higher their risk for complications after bariatric surgery, such as higher rates of emergency...
Gastrointestinal Disease Tied to High Physical, Financial Burden
FRIDAY, April 18, 2025 -- Gastrointestinal (GI) diseases are responsible for a considerable and growing burden of health care use and costs within the United States, according to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.